Significant transactions and performance updates around
Laboratory Corporation of America Holdings (NYSE:LH) continue to impact the market. Notable activity includes
BNP Paribas selling 65,035 shares, while
Bank of Montreal and several other firms, like
Financial Counselors Inc. and
Mutual of America Capital Management LLC, are increasing their stake. Furthermore, the company's stock has hit a
52-week high at $239.65. Their winning bid for select assets of
Invitae expands their offerings, and the acquisition of specific assets from
BioReference Health's Diagnostics Business stands to strengthen their position. Recent
Q1 and Q2 earnings have surpassed estimates, contributing to stable performance. Their decision to increase
mpox testing capacity signifies adaptability in market needs. Still, a few disappointments such as Q3 and full year 2023 earnings missing expectations, hint at areas for growth. The recent spin-off of their
Fortrea unit has slightly dampened profit forecasts for 2023, outlined in the firm's Q1 2024 Earnings Call and Webcast.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 23 Jul 2020 07:00:00 GMT to Sat, 30 Nov 2024 09:49:26 GMT -
Rating 7
- Innovation 5
- Information 5
- Rumor -3
